Device Trial Radar · NCT06034652
T-GENVIH-003 LTFU (Long Term Follow Up) Study
Last checked: Nov 19, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Sep 12, 2023
Primary completion
Jan 19, 2024
Study completion Jan 19, 2024
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical approach cases) from the prior T-GENVIH-002 study.
Conditions
- Hernia
- Hernia, Ventral
- Pathological Conditions, Anatomical
- Hernia, Abdominal
Interventions
Integra® Gentrix® Surgical MatrixDevice
Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinically Confirmed RecurrenceTime frame: Through study completion, an average of 4 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Surgical Healing Arts
Fort Myers, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.